A Prospective Study of Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: The Keystone-001 Trial

Background and Research Motivation Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive cancer, especially in locally advanced stages. Traditional neoadjuvant chemoradiotherapy (NCRT) is the standard treatment method for this type of cancer. Despite its significant therapeutic effects, local recurrence and distant metastasis rates remai...